Oxfordshire mum with brain tumour backs research funding calls
Georgie Maynard has suffered from regular migraines all her adult life, but one Saturday lunchtime in May 2023 she knew something wasn't right."I went out to the garden to get some fresh air and I thought 'no, this light is doing my head in' so I walked inside, sat on the sofa and then it just went bang! "It was excruciating... I actually thought that was it, I was dying at that moment."The mother of five from Oxfordshire had suffered a sudden seizure.Her children called an ambulance and paramedics arrived within minutes. The 46-year-old was taken to hospital and given a CT scan then sent home.The following week an MRI scan revealed she had a grade four glioblastoma (GBM) - an aggressive brain tumour."It's the worst type of brain tumour," she said."One in four live past a year, five per cent last five years."It's quite shocking. At that point you've got no belief that that's coming at your door because it's completely out the blue."
Mrs Maynard underwent an awake craniotomy as well as radiotherapy and chemotherapy. Her latest scan showed the tumour was stable, but she is aware that the average life expectancy following diagnosis is 12 to 15 months.According to Cancer Research UK, glioblastomas are the most common type of cancerous brain tumour in adults and remain the biggest cancer killer of children and adults under the age of 40.However, just one per cent of the national spend on cancer research is allocated to the disease.
Mrs Maynard is keen to raise awareness of the condition and do all she can to ensure funding for research is made a priority.Together with her brother, Charlie Maynard - the Liberal Democrat MP for Witney - Mrs Maynard visited the Centre for Medicines Discovery at Oxford University.A team led by Prof Daniel Ebner is working on a five-year study to identify existing cancer drugs that might be able to shrink brain tumours.Out of 10,000 drug combinations, only half a dozen have real potential.
'Fantastic breakthoughs'
While clinical trials would still be required, because they have already been approved by regulators, Prof Ebner said they could be given to patients within the next five years."I'm optimistic for glioblastoma research. Some of the best scientists I've ever worked with are making fantastic breakthroughs," Prof Ebner said.He added: "Where we would definitely need additional help is with funding to carry a lot of the pre-clinical work we've done to date through to clinical trials. That's the major stumbling block at the moment."In 2018, the government pledged to invest £40m in research into brain tumours and improve access to clinical trials, following the death of Dame Tessa Jowell.Nearly seven years later, only about £15m of that £40m has been spent, according to the Brain Tumour Charity.Mr Maynard said he wanted to know why the remaining money has not been invested.He said: "There's tonnes of really good research that's crying out for money. It's not doing any good sitting in a bank and I really want some answers."Does it exist... and then what are we going to do to spend it and start saving some lives?"
A spokesperson for the Brain Tumour Charity said: "A sustainable and strategic approach to government funding for research into brain tumours is long overdue in order to make progress. "This should include a broad range of research projects from early-stage understanding - like Prof Ebner's - to late-stage trials."At The Brain Tumour Charity we are proud to fund a comprehensive and robust research programme and can only do so thanks to supporters like Georgie."A Department of Health and Social Care spokesperson said: "We will build on Tessa Jowell's powerful legacy to improve both research and care for brain cancer patients across the UK."We spend more than £1.6bn annually on health research and have recently launched two new calls for studies unlocking the next generation of treatments for brain cancer."
You can follow BBC Oxfordshire on Facebook, X, or Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
an hour ago
- The Independent
What we know about the new NHS cervical screening guidelines
New NHS guidelines in England will invite women aged 25-49 with negative HPV tests to cervical screenings every five years instead of every three, starting next month. The change follows recommendations from the UK National Screening Committee and aligns England's screening intervals with those of Wales and Scotland. Analysis from King's College London indicates that extending the screening interval to five years for HPV-negative women maintains a similar rate of cancer detection as the current three-year interval. Health Minister Ashley Dalton stated the change aims to increase testing opportunities for women with HPV while extending screening intervals for those with negative tests, emphasising early detection and treatment. Experts encourage women to attend screenings when invited, with the NHS implementing measures like phone reminders to improve participation, while Cancer Research UK highlights the impact of screening and HPV vaccination on reducing cervical cancer rates.
The Independent
2 hours ago
- The Independent
The therapy that could help prevent food-related liver cancer
New research has identified a pathway involving the genes p53 and TIGAR that may prevent fatty liver disease from progressing to liver cancer, a condition for which there are currently no effective treatments. Researchers from Glasgow Caledonian University, the Cancer Research UK Scotland Institute, and The Francis Crick Institute discovered that p53 protects the liver from high-fat, high-sugar diets through the gene TIGAR, which acts as an antioxidant and detoxifies lipids in a fatty liver. The breakthrough suggests that antioxidant therapy could be developed to mimic the protective response of p53 and TIGAR, potentially preventing the development of key features of fatty liver disease. Dr. Timothy Humpton noted that the research establishes a key role for p53 and TIGAR in protecting against the progression from liver disease to liver cancer, suggesting that targeting this pathway through antioxidants is of great interest for future therapies. He also highlighted that fatty liver disease, often caused by poor diet and lack of exercise, is hard to diagnose due to its asymptomatic nature.
The Independent
14 hours ago
- The Independent
Groundbreaking cancer treatment which ‘destroys tumours with sound' to be rolled out on NHS
NHS patients will be the first in Europe to benefit from a pioneering new cancer treatment which uses ultrasound to destroy tumours. The technology, known as histotripsy, offers a non-invasive treatment capable of breaking down liver cancer tissue without surgery, radiation or chemotherapy, with minimal damage to the surrounding organs, according to the Department for Health and Social Care (DHSC). First approved by US regulators in October 2023, histotripsy uses pulsed sound waves to create 'bubble clouds' from gases present in the targeted tissue and tumour. When these bubbles pop, within microseconds, a shockwave is released which is capable of breaking up a mass and killing cancerous cells, while avoiding the harms of radiation and reducing the risks of bleeding, infection, and damage to surrounding non-targeted tissue. Treatment is delivered via a single session – potentially taking just 30 minutes – with limited or no pain, a quick recovery, and can be performed as a day case, according to the DHSC. The first NHS patients are set to be treated this summer at Addenbrooke's Hospital in Cambridge, where the technology – which uses a device called an Edison System, created by US firm HistoSonics – is being debuted after a donation from the Li Ka Shing Foundation. Cancer Research UK describes liver cancer as the 17th most common cancer in the UK and the 8th most frequent cause of cancer death. More than 8,000 people received a new diagnoses in 2022, with liver cancer incidence across the UK having surged by 42 per cent over the past decade, according to the British Liver Trust. So far, more than 1,500 patients worldwide have received treatment using histotripsy, mainly in the United States – following approval by the US Food and Drug Administration in late 2023. According to 12-month follow-up data from HistoSonics' previous clinical trials, which involved patients for whom other treatments had been either unsuccessful or unavailable, overall survival rates after one year were 73.3 per cent for primary liver cancer, and 48.6 per cent for those with secondary tumours. The paper, published in the Annals of Surgery journal in April, noted that both tumour control and survival rates were similar to those among other current treatments. The UK's new device is expected to be fully installed in Cambridge later this year, where it will be used initially to treat patients with primary and secondary liver tumours. Wider research on how this could potentially treat tumours in other organs – such as the pancreas and kidneys – is underway. The technology has been approved in the UK via the innovative devices access pathway, which aims to enable faster approvals of medical devices and treatments which evidence shows are safe, efficient and can fill unmet need. 'This is a strong example of smart, agile regulation in action,' said James Pound, of the Medicines and Healthcare products Regulatory Agency (MHRA). 'It's a major step forward for patients with liver cancer and shows how the UK can be a frontrunner in supporting responsible innovation that meets real clinical need.' While 'regulation is vital to protect patients', the government is 'slashing red tape, so game-changing new treatments reach the NHS front line quicker – transforming healthcare', said health secretary Wes Streeting. Hailing histotripsy as 'an exciting new technology that will make a huge difference to patients', Roland Sinker, chief executive of Cambridge University Hospitals, said: 'By offering this non-invasive, more targeted treatment we can care for more people as outpatients and free up time for surgeons to treat more complex cases. 'The faster recovery times mean patients will be able to return to their normal lives more quickly, which will also reduce pressure on hospital beds, helping us ensure that patients are able to receive the right treatment at the right time.' Fiona Carey, a kidney cancer patient who co-chairs Cambridge's patient advisory group, added: 'This is seriously good news. A new, non-invasive option to treat these cancers is very welcome indeed. 'For patients for whom ordinary surgery is no longer an option, this could make all the difference.'
